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Background: Pigs have been implicated as mixing reservoir for the generation of new pandemic influenza strains,
control of swine influenza has both veterinary and public health significance. Unlike human influenza vaccines,
strains used for commercially available swine influenza vaccines are not regularly replaced, making the vaccines
provide limited protection against antigenically diverse viruses. It is therefore necessary to develop broadly
protective swine influenza vaccines that are efficacious to both homologous and heterologous virus infections. In
this study, two forms of DNA vaccines were constructed, one was made by fusing M2e to consensus H3HA (MHa),
which represents the majority of the HA sequences of H3N2 swine influenza viruses. Another was made by fusing
M2e and a conserved CTL epitope (NP147-155) to consensus H3HA (MNHa). Their protective efficacies against
homologous and heterologous challenges were tested.
Results: BALB/c mice were immunized twice by particle-mediated epidermal delivery (gene gun) with the two
DNA vaccines. It was shown that the two vaccines elicited substantial antibody responses, and MNHa induced more
significant T cell-mediated immune response than MHa did. Then two H3N2 strains representative of different
evolutional and antigenic clusters were used to challenge the vaccine-immunized mice (homosubtypic challenge).
Results indicated that both of the DNA vaccines prevented homosubtypic virus infections completely. The vaccines’
heterologous protective efficacies were further tested by challenging with a H1N1 swine influenza virus and a
reassortant 2009 pandemic strain. It was found that MNHa reduced the lung viral titers significantly in both
challenge groups, histopathological observation showed obvious reduction of lung pathogenesis as compared to
MHa and control groups.
Conclusions: The combined utility of the consensus HA and the conserved M2e and CTL epitope can confer
complete and partial protection against homologous and heterologous challenges, respectively, in mouse model.
This may provide a basis for the development of universal swine influenza vaccines.
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Swine influenza virus (SIV), member of genus Influenza A
virus of the family Orthomyxoviridae, is a common and
important causative pathogen involved in the porcine re-
spiratory disease. Mortality of SIV-infected pigs is low, but
morbidity may approach 100%. Clinical signs of swine in-
fluenza include high fever, lethargy, anorexia, coughing,
labored breathing and nasal discharge. Synergistic or sec-
ondary infections with opportunistic organisms may in-
crease the severity of clinical disease [1]. Beyond the
veterinary implications, influenza virus infections in pigs
also present an important public health risk. Since pigs ex-
press sialic acid receptors for both mammalian and avian
strains of influenza viruses on their tracheal epithelial cells
[2], they could potentially serve as “mixing vessels” for the
generation of new reassortant strains of influenza viruses
that have pandemic capacity. The recently emerged 2009
pandemic H1N1 which resulted in over 18,449 deaths is
an example (http://www.who.int/csr/don/2010_08_06/en/
index.html). Genetic analyses revealed that this pandemic
H1N1 influenza virus is a triple reassortment of multiple
strains of viruses circulating in the North America and
Eurasia swine population [3,4]. Therefore, SIV-infection
control would be of benefit to both reduce the economic
losses of swine industry and human health.
Vaccination is considered to be the most effective
method to control SIVs. Currently, commercially avail-
able swine influenza vaccines are adjuvanted, whole-
virus killed vaccines. Although the vaccines reduce the
severity of disease and the extent of virus shedding in
pigs after challenge, they do not provide consistent pro-
tection from infection [5]. The vaccines function by tar-
geting the surface glycoprotein hemagglutinin (HA), the
most variable influenza virus antigen. Protective effi-
cacy depends on the antigenic match degree between vac-
cine and circulating strains. However, influenza viruses
continuously evolve by increasing the mutations in epi-
topes (antigenic drift) or by reconstituting the genome
with other strains (antigenic shift). The increased incidence
of avian-like or human-like SIV reassortants, which exhibit
great genetic diversity and thus antigenic diversity with
classical SIVs, has been documented [6-8], resulting in the
“antigenic mismatch” between vaccine and the circulating
strains. In addition, each of the dominant subtypes circulat-
ing in swine population worldwide, i.e. H1N1, H3N2 and
H1N2, has developed multiple genetic clusters based on
the phylogenetic analysis of HA genes [9-12]. Previous
studies have demonstrated that some viruses in different
clusters showed only limited cross-reactivity [10,12], sug-
gesting that the genetic and antigenic heterogeneities within
each subtype may reduce the vaccines’ effectiveness [13-
16]. Vaccines that induce broad protective immunity
against diverse SIV clusters and even subtypes, or limit the
spread of the viruses between pigs and humans, especiallyfor pandemic strains, are therefore needed. Consensus HAs
of different strains within one subtype were previously
studied for eliciting cross-cluster protection [17], but HA
induces predominately a subtype-specific humoral immune
response. In contrast, the conserved viral antigens, such as
M2e and internal NP, can generate heterosubtypic immun-
ity protective against diverse virus strains and subtypes [18-
21]. Unlike HA, the NP-induced cell-mediated immune
responses do not prevent infection, but reduce the severity
of illness and accelerate the virus clearance. It is reasonable
to propose that the combined utility of the consensus HA
and conserved viral proteins will confer complete protec-
tion against homosubtypic and, at least partial, heterosubty-
pic challenge. In the present study, two types of swine
influenza DNA vaccines were constructed: (1) fusing matrix
2 ectodomain (M2e) to consensus HA of H3 subtype SIV
(MHa, means M2e+HA) and, (2) fusing M2e and a con-
served CTL epitope, NP147-155, to consensus H3 HA
(MNHa, means M2e+NP147-155+HA). Then their pro-
tective efficacy and broadness against divergent H3N2
and H1N1 SIV challenges were tested in mice.
Results
The DNA vaccines elicited M2e- and HA-specific
antibodies
To increase the expression level, the M2e, CTL epitope
and consensus H3 HA gene was optimized for codon
usage, RNA structure and GC content. Then the codon-
optimized consensus HA, linked with M2e, was cloned
into eukaryotic expression vector with or without
NP147-155 to generated two DNA vaccines (Figure 1).
After nucleotides sequencing, the DNA vaccine plas-
mids were transfected into human embryonic kidney
(HEK) 293 T cells,the expression of each chimeric
protein was confirmed by indirect immunofluores-
cence assay (IFA). IFA showed that both M2e and
HA genes expressed in vitro (data not shown). Then
the two DNA vaccines, as well as empty vector, were
coated with gold particles and delivered into the skin
with a gene gun. Humoral immunity was analyzed by
detecting the presence of antigen-specific antibodies.
As can be seen in Figure 2, each of the constructs
evoked a substantial HA-specific IgG response after
the booster injection, suggesting that the two vaccines
were adequately delivered and expressed in mice. No
significant difference in serum IgG antibody levels
were observed between MHa and MNHa group
(p> 0.05), indicating that the addition of a 9-mer
length CTL epitope did not influence the vaccine’s
antibody-inducing ability significantly. But the anti-
body titer of M2e was lower than that of HA
(p< 0.001). This is not surprising, because M2e con-
tains only 24 amino acids and it was reported that
M2e is less immunogenic than HA [22].
Figure 1 Schematic diagram of the construct design for two DNA vaccines. tPA: signal peptide of tissue plasminogen activator; (G4S)3:
Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser linker.
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and heterosubtypic virus to assess the ability of inducing
relevant and cross-reactive functional antibodies. As
detailed in Table 1, both of the vaccine immunization
groups developed HI antibodies against homologous
viruses, but induced very low levels of HI antibodies
against heterologous viruses.
NP147-155 enhanced CTL responses significantly
The ability of the CLT epitope-containing vaccine,
MNHa, to induce cellular immune response was deter-
mined by IFN-γ ELISPOT assay. A synthesized peptide
NP147-155 was used for restimulating splenocytes iso-
lated from 3 mice of each group. Results showed that,
after restimulation, the number of activated IFN-γ se-
creting cells from mice immunized with MNHa was sig-
nificantly higher than that from mice immunized with
MHa and empty vector (p< 0.001, Figure 3).
Both MHa and MNHa vaccination conferred complete
protection against homologous challenge, but MNHa
showed more significant cross-protection against
heterologous challenge than MHa did
Our previous study indicated that the wild type of
SwGD164 strain (H1N1) replicates poorly in mice (un-
published data). To make the virus be suitable for vaccine
efficacy assessment in vivo, we constructed a recombinant
virus (r164) by using reverse genetics. r164 contains HA
and NA from SwGD164, and the internal proteins from
PR8. BALB/c mice were infected intranasally with two
homologous strains belonging to different clusters withinFigure 2 HA- and M2e-specific antibody response to MHa and MNHa
each construct by using gene gun. Blood were collected 21 days after 2nd
M2e peptides, respectively. OD450 at each dilution were determined by indH3 subtype 21 days after the last immunization [9]. Mice
lungs were taken 3 days post infection for virus titration
and histopathologic changes observation. Results demon-
strated that there was no detectable virus load in all the
vaccine-immunized mice, while empty vector control
group showed high lung viral titers (Figure 4). In addition,
histopathologic observation showed no obvious histo-
pathologic changes in vaccinated mice. In contrast, the
empty vector control group exhibited histopathological
damages including the dropout of mucous epithelium
cells, interstitial edema, hyperemia, hemorrhage, and in-
flammatory cell infiltration (Figure 5).
Since M2e and NP147-155 are conserved in different
subtypes of influenza viruses, we hypothesized that the
DNA vaccine can confer partial protection against het-
erosubtypic challenge. To test this, the vaccines’ protect-
ive ability was studied in mice challenged with H1N1
SIVs, which are also circulating in swine population
worldwide. The immunized mice were challenged with
heterologous G11 and rPan09, respectively. Lung viral
titers determination and pathological analysis were per-
formed as described above. Results indicated that all the
mice that had been vaccinated with MHa had a detect-
able virus level, although showed a reduction in mean
viral titers in both challenge groups compared with vec-
tor control, the reduction did not reach significance
(p= 0.06 for rPan09 group and p= 0.67 for G11 group,
Figure 4). Histopathological analysis exhibited corre-
sponding results, i.e., mice of MHa group had lung path-
ology as almost severe as vector inoculated group. In
MNHa group, although the mice also exhibited detectablevaccinations. Mice were immunized twice, three weeks apart, with
shot. ELISA plates were coated with inactivated SwHLJ1 and synthetic
irect ELISA.
Figure 4 Protection of mice from homologous and
heterologous challenges. Mice lung viral titers at day 3 after
challenges were determined in eggs from an initial dilution of 1:10
in phosphate-buffered saline and expressed as EID50/ml. The limit of
virus detection was 1.5log.
Table 1 Serum HI titers for homologous (H3) and
heterologous (H1) strains
HI titers (GMT)
H3 subtype H1 subtype
SwHLJ1 r164 rPan09 G11
MHa 253 320 13 16
MNHa 202 253 10 13
pCAGGS <10 <10 <10 <10
Sera from each immunized group was pooled, results represent geometric
mean titers of 3 independent experiments. Start dilution of sera was 1:10.
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reduced in both rPan09- and G11-challenged groups com-
pared to vector-immunized control (p< 0.001), showing
average viral titer reduction of 3.4 and 2.1 logs, respect-
ively (Figure 4). As expected, pathology damage of mice
lung of MNHa group was less pronounced than that of
MHa and vector control group, moderate histopatho-
logical lesions, mainly vascular congestion and various
degrees of hemorrhage were observed (Figure 5). Collect-
ively, these findings indicate consensus HA in combin-
ation with M2e elicits cross-cluster immunity, and CTL
response contributes to the control and clearance of infec-
tion and reduces pathogenesis.
Discussion
Although the viruses are highly and continuously variable
because of antigenic drift and shift, influenza is a vaccine-
preventable disease. The conventional inactivated humanFigure 3 Number of IFN-γ secreting cells measured by ELISPOT.
Spleen cells were harvest from 3 mice 2 weeks after the last
immunization, then pooled and restimulated by peptide of NP147-
155. Results were expressed as spot-forming cells (SFC) per million
splenocytes. Data are representative of 3 independent experiments.influenza vaccines are updated annually with the World
Health Organization-recommended H1N1, H3N2, and in-
fluenza B strains in order to antigenically match the
viruses predicted to be the most likely to cause the next
epidemic. Unlike human influenza vaccines, strains used
for swine influenza vaccines preparation are not regularly
replaced, making the vaccines provide limited protection
against antigenically diverse SIVs. A universal vaccine
designed based on the conserved viral proteins that
confers broad protection is an attractive solution to
counter the features of highly variable of not only
human but also swine influenza viruses. Many studies
developed universal vaccines against human influenza,
whereas broadly responsive swine influenza vaccines,
to our knowledge, have not been reported.
The virus envelope glycoprotein HA is the most abun-
dant surface protein, antibodies against HA can provide
protection by blocking virus attachment and entry. Stud-
ies from several groups have demonstrated the antiviral
efficacy of consensus HA as an “intra-subtype” universal
vaccine. The study of Chen et al. [17] showed that the
consensus H5 HA-based DNA vaccine elicited only
moderate neutralization activities toward the H5N1
clade 2.1 and clade 2.3 viruses, and provided not
complete, albeit significant, protection against clade 2.1
virus, suggesting that consensus HA alone may be not
enough to induce complete protection against all strains
within one subtype, much less heterosubtypic strains.
However, ideally, universal vaccines should be capable of
inducing protection against both homosubtypic and het-
erosubtypic challenges. To this end, we linked M2e and
CTL-inducing epitope NP147-155 to consensus H3 HA to
construct a universal swine influenza vaccine. The reasons
we chose M2e and NP147-155 are: (1) both of them are
highly conserved among different SIV strains, NP147-155
are even conserved among human, avian and swine
Figure 5 Histopathology analysis of lungs from the mice inoculated with SwHLJ1 (A, B, C), r164 (D, E, F), rPan09 (G, H, I) and G11
(J, K, L) at day 3 post inoculation, after immunized with MHa (A, D, C, J), MNHa (B, E, H, K) and pCAGGS vector (C, F, I, L).
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ability to broaden the protective scope of the vaccine. (2)
NP147-155 induces a vigorous CTL response [23]. Studies
indicated that specific CTLs provide some level of cross-
protection against antigenically distinct viruses of not only
the same subtype but also different subtypes [24,25].
Previously we have shown that SwHLJ1 and SwGD164
had evolved into 2 independent lineages based on the
phylogenetic analysis of the HA gene. To see whether
the two strains were antigenically distinct, cross-HI assay
was performed by using r164-specific anti-serum. It was
found that the titer of cross-reacting HI antibodies
(SwHLJ1-reacting) was significantly lower than that of
r164-reacting HI antibodies (p< 0.001, data not shown),
thus suggesting that they belong to different antigenicTable 2 Amino acids homology of HA, M2e and
NP147-155 between the vaccine and challenge strains
Challenge strain % homology of amino acids
HA M2e NP147-155
H1 subtype rPan09 44.3 79.2 100
G11 44.0 79.2 100
H3 subtype SwHLJ1 93.3 91.7 100
r164 95.1 79.2 100clusters. Results of present study demontrated that both
MHa and MNHa vaccination provided complete protec-
tion against these two viruses challenges, cross-cluster
protections were therefore suggested. While MNHa, but
not MHa, induces immune responses partially protect
against heterologous influenza infection, suggesting the
echanced T-cell mediated response is not required for
homologous protection. Results also further confirm that
CTL responses play important roles for heterologous
protection, meaning that strengthening CTL responses
are promising ways for universal influenza vaccines
development.
It was established that the 2009 pandemic H1N1virus
is pathogenic and is readily transmitted in pigs [26-29].
Although the new H1N1 virus is now considered to be
post-pandemic, the possibility that it recombines with
other influenza viruses in pigs then yielding a novel po-
tential epidemic or pandemic strain still exists[30]. Here
in this study, the mice were partially protected from the
reassortant 2009 pandemic virus challenge after the
immunization of MNHa. The vaccine immunization
inhibited the pulmonary viral replication significantly in
mice, thus could accelerate the virus clearance, and re-
duce the potential of transmission and the risk of recom-
bination. Although the heterologous protection elicited
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has a large potential for improvements. The present
study lays the foundation for universal swine influenza
vaccine development, and call for further investigations
in which the heterologous immune response should be
further enhanced, such as the addition of molecular adju-
vants [31,32] and/or more copies of conserved viral pro-
tein encoding genes [33], and the usage of DNA-prime
protein/virus-boost immunization schedule [34,35]. A pre-
vious study conducted by Heinen et al. constructed a
DNA vaccine containing M2e and full length of NP genes,
but HA encoding gene was not included. Their data
showed that the M2e-NP DNA vaccination produced en-
hancement of disease after challenge [36]. Although the
mechanism underlying which is unclear, we think the HA
may play roles in this discrepancy between the results of
Heinen et al.’s and ours. Another possible reason should
be taken into consideration is that gene gun immunization
induces more strong immune response that the conven-
tional needle injection method, which was used in Heinen
et al.’s study [37]. It is necessary to study whether the
DNA vaccines we developed here will confer protection in
pig models. Also, it would be interesting to study how, if
does, the HA protein influence the vaccines’ efficacy.
Conclusions
The combined utility of the consensus HA and the con-
served M2e and CTL epitope can confer complete and
partial protection against homologous and heterologous
challenges, respectively, in mouse models. This may pro-
vide a promising strategy for universal swine influenza
vaccine development.
Materials and methods
Viruses, cell and mice
Swine influenza viruses of A/Swine/Heilongjing/1/05
(H3N2) [SwHLJ1], A/Swine/Guangdong/164/06 (H3N2)
[SwGD164] and A/Swine/Guangdong/1/01(H1N1) [G11]
were isolated previously by us [6]. Briefly, clinical samples
from diseased pigs were homogenized in phosphate-
buffered saline (PBS) containing antibiotics, then inocu-
lated into allantoic cavities of specific pathogen free (SPF)
embryonated chicken eggs, the eggs were incubated for at
least 48 h at 35°C. Virus isolate was passaged and identi-
fied by hemagglutination inhibition (HI) test and neur-
aminidase inhibition (NI) test using a panel of reference
sera. Reassortant virus with surface glycoproteins of 2009
pandemic A/Califorina/04/2009 and internal proteins of
PR8 virus (abbreviated as rPan09) was kindly provided by
Drs. Wen-Bao Qi and Ming Liao of College of Veterinary
Medicine, South China Agricultural University. r164, con-
taining SwGD164 surface glycoproteins and PR8 internal
proteins, was prepared by using reverse genetics as
described [38]. These viruses were propagated in allantoiccavities of 9 to 10-day old SPF embryonated chicken eggs
and stored at −80°C until use. Fifty-percent embryo infec-
tious dose (EID50) titers were determined by serial titration
in embryos and calculated by the method of Reed and
Muench [39]. HEK 293 T cells were maintained in Dulbec-
co's modified Eagle's medium (DMEM, Sigma) supple-
mented with 10% fetal bovine serum in humidified 5%
CO2 atmosphere at 37°C. SPF female BALB/c mice
(4–6 weeks of age) were purchased from Shanghai
SLAC Laboratory Animal Co., Ltd., and maintained
with free access to sterile food and water. All animal
studies were conducted in accordance with the ethical
guidelines and were approved by the Ethical Committee
of Shanghai Veterinary Research Institute, Chinese Acad-
emy of Agricultural Sciences.
Plasmid construction
A total of 162 HA and 105 M2 sequences with full-length
of H3N2 subtype SIV were, respectively, downloaded from
GenBank database and aligned by MegAlign program sup-
plemented in DNASTAR package (DNASTAR Madison,
WI). The consensus sequences were created based on the
most common amino acid in each position of the align-
ment. After the consensus M2 sequence was generated,
the first 24 amino acids were selected as M2e motif [40].
Then codons of the consensus HA, as well as M2e and an
immunodominant cytotoxic T lymphocyte (CTL) epitope
of the NP protein, NP147-155 (TYQRTRALV) [41], were
optimized for mammalian expression and synthesized by
GenScript Corporation (Nanjing, China). The (G4S)3-
linked chimeric ORF encoding M2e, CTL epitope and
consensus HA was PCR-amplified by introducing 5’ Sma I
and 3’ Nhe I restriction sites for ligation into the pCAGGS
vector, under the control of the cytomegalovirus (CMV)
enhancer and chicken β-actin promoter (designated as
MNHa). Similarly, MHa was designed and constructed,
except that the CTL epitope was omitted from the N-
terminal end of the consensus HA (Figure 1). After the re-
combinant plasmids being identified by nucleotide se-
quencing, they were propagated in E. coli bacteria and
purified using Mega purification kit (Qiagen, Valencia,
CA) for in vitro transfection as well as in vivo animal
immunization. The final DNA preparations were resus-
pended in nuclease-free water and stored at −20°C until
further use.
In vitro expression of recombinant protein
HEK 293 T cells were seeded in 6-well plates and trans-
fected at 80-90% confluence with 4 μg of MHa, MNHa or
empty vector using Lipofectamine 2000 transfection re-
agent (Invitrogen), as recommended by the manufacturer.
After 48 h, the transfected cells were scraped from the
culturing plate, washed with PBS, then spotted onto a
glass slide, air dried, and fixed with pre-chilled acetone.
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cells were incubated with anti-M2e and -HA polyclonal
antibodies for 1 h at 37°C. A secondary Alexa Fluor 568-
conjugated goat anti-mouse IgG antibody was then used
to detect the primary antibody. Fluorescence images were
scanned using an inverted microscope after the samples
were mounted by glycerol.
Gene gun delivery of DNA and virus challenge
Gene gun immunization was performed as previously
described [42,43]. Mice received two nonoverlapping ab-
dominal deliveries of antigen encoding plasmid- or empty
vector-coated gold beads (1 μm) at the shaved skin with a
3-wk interval. With each shot, 2 μg of DNA immobilized
onto 0.5 mg gold particles was delivered at a helium dis-
charge pressure of 450–500 psi with a Helios gene gun
(Bio-Rad). Each test group contained 43 mice with
experiments organized as follows: (1) 3 mice of each
group were used to complete IFN-γ ELISPOT assays
on day 21 post the 2nd immunization; (2) the left 40
mice of each group were divided as 4 subgroups, each
comprised of 10 mice, then intranasally challenged
with 106 EID50 of two H3N2 (SwHLJ1 and r164) and
two H1N1 (G11 and rPan09) strains, respectively, at
21 days after the final immunization.
Serologic testing
Serum samples were collected from orbital bleeds on
day 14 post last immunization. M2e and HA antibody
titers were measured using indirect ELISA. ELISA
plates were coated overnight with synthetic M2e pep-
tides or inactivated SwHLJ1 in 0.1 M carbonate buffer
(pH 9.6) at 4°C and blocked with 5% non-fat milk for
2 h at 37°C. A series of two-fold dilution of sera
(starting dilution 1:500 for HA and 1:100 for M2e,
100 μl/well) were incubated at 37°C for 1 h, followed
by three washes with PBST. Then HRP-conjugated
goat anti-mouse IgG (Zhongshan Biotechnology Co.,
Ltd Beijing, China) and 3,3'-5,5'-tetramethyl benzidine
(TMB) was used for M2- and HA-specific antibody
detection and color development, respectively. The result-
ing optical density (OD) at 450 nm was determined with
a plate reader after the reaction was stopped with
2 M H2SO4.
HI assays were performed using 0.5% chicken red
blood cells (RBCs) with 4 HA units of homologous
(SwHLJ1 and r164) and heterologous (G11 and rPan09)
virus and receptor-destroying enzyme (RDE, sigma) trea-
ted serum, as previously described [44]. The reciprocal of
highest dilution of serum that gave complete inhibition of
hemagglutination was considered the HI titer. Each assay
was performed in triplicate. A titer of less than 10 (starting
serum dilution) was assigned for serum samples that did
not inhibit hemagglutination.IFN-γ ELISPOT
The ELISPOT assays were performed using mouse IFN-
γ ELISPOT kits following methods recommended by the
manufacturer (Dakewe Biotech, PR China). Briefly, single-
cell suspensions of freshly isolated spleen lymphocytes
were seeded into the plates (106/well) pre-coated with
anti-IFN-γ monoclonal antibody. Cells were stimulated
with synthesized NP147-155 peptide at a final concentra-
tion of 5 μg/ml in a 37°C humidified incubator with 5%
CO2. Phytohemagglutinin (PHA, 5 μg/ml) and medium
alone were used as positive and negative controls, re-
spectively. After a 36 h culture, plates were washed
and incubated for 1 h with biotinylated anti-mouse
IFN-γ antibody. Streptavidin-horseradish peroxidase was
then added, IFN-γ spots were developed with 3-amino-9
-ethylcarbazole (AEC) and counted using an automated
ELISPOT reader. Results were expressed as spot-forming
cells (SFC) per million cells.
Lung viral titer measurement and histopathological
examination
On day 3 post-infection, mice from each group were
sacrificed to collect lungs for virus titration and patho-
logic examination to determine the protective ability of
DNA vaccines. For virus titration, the whole lungs were
homogenized in 1 mL of sterile phosphate-buffered sa-
line (PBS) containing 0.1 mg/ml of streptomycin and
100 IU/ml of penicillin. The homogenates were diluted
10-fold serially after being centrifuged, then inoculated
into embryonated chicken eggs. Infection within individ-
ual eggs was confirmed using a standard hemagglutination
assay, the viral titers were determined by the method of
Reed and Muench.
Lung tissue histopathologic sections were made as
described elsewhere [45]. Briefly, the removed lungs
were fixed in 10% neutral buffered formalin, dehydrated
and embedded in paraffin. Five micrometer sections
were cut and stained with hematoxylin and eosin (H&E),
and reviewed for histopathologic changes.
Statistical analysis
Data of experimental and control groups were presented
as the averages ± standard error (SE) and evaluated by
ANOVA method, where statistically significant results
were defined as having a p value of less than 0.05.
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